
Risultati per 'Covance':
Di seguito l'elenco dei risultati di ricerca trovati rilevanti per la keyword 'Covance':
Risultati maggiormente rilevanti:


Labcorp Drug Development (formerly Covance) is a global contract research organization (CRO) that provides drug development services with the goal of advancing health. We have supported the development of the top 50 pharmaceutical drugs on the market. As a full-service CRO, we are dedicated to providing nonclinical, preclinical, clinical, commercialization and regulatory consulting, research ...


Labcorp Drug Development is a contract research organization (CRO) headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, [3] the company is part of Labcorp, which employs more than 70,000 people worldwide.


Chiltern | 60.767 follower su LinkedIn. Chiltern, a Covance company – is now Covance Clinical-Biotech. Follow Covance for the latest updates from us. | We’ve moved. Chiltern, a Covance company – is now Covance Clinical-Biotech. One name in clinical trials.
Altri risultati:


© 2022 Labcorp. All rights reserved. Version 2022.0.5; Terms and Conditions; Privacy policy; Contact Us


BURLINGTON, N.C. -- (BUSINESS WIRE)--May 28, 2020-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, is expanding its technology ecosystem to accelerate the adoption of decentralized clinical trials, often referred to as ...


The people said Syneos’s management would run the merged company, although its leadership would include executives from Covance, which has changed its name to Labcorp Drug Development. The talks ...


This site is for the exclusive use of Labcorp Drug Development clients. Any other attempt at usage is strictly prohibited. Labcorp has security procedures in place for the purpose of protecting the security of data available through Xcellerate Investigator Portal, both technical and operational measures, including the use of passwords, restricted access to databases, the use of 128-bit ...